secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2021-12-22T23:59:59+00:00
Accession:  0001104659-21-152368
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering acquires BioArkive for $8.75M in stock; delays IMM-1-104 IND to Q3 2022
--------------------------------------------------------------------------------

- Acquired BioArkive for $8.75M in stock (379,635 shares); BioArkive CRO to be fully integrated into Immuneering.
- Assumed BioArkive's San Diego lease: 38,613 sq ft, monthly base rent ~$56K, term through April 2032.
- IMM-1-104 IND submission delayed to Q3 2022; first patient enrollment now Q4 2022 due to supply chain constraints.
- 28 BioArkive employees become Immuneering employees; Brett Hall (Immuneering CSO) held majority of BioArkive shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000110465921152368/0001104659-21-152368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000110465921152368/tm2136034d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-152368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer